Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat short-term insomnia, which is marketed under the brand name of Ambien or Stilnox; invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer; OroMist, an oro-mucosal technology that delivers a range of drug classes through the cheeks, gums, tongue, or floor of the mouth; and Anagrelide to treat cancer. The company also develops oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Arovella Therapeutics Dividend Announcement
• Arovella Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Arovella Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.
Arovella Therapeutics Dividend History
Arovella Therapeutics Dividend Yield
Arovella Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Arovella Therapeutics stock? Use our calculator to estimate your expected dividend yield:
Arovella Therapeutics Financial Ratios
Arovella Therapeutics Dividend FAQ
1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.
2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.
3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.
4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.
5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Place an order: Use the brokerage's trading platform to place an order to buy Arovella Therapeutics stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.